About
Pipeline
Clinical Trials
Partners
News
Careers
Contact Us
News
Press Releases
Press Kit
Recent Press Releases
11/8/2012
Plexxikon Announces Three-Year Survival in Zelboraf-Treated Metastatic Melanoma Patients
2/19/2012
Plexxikon Announces European Approval of Zelboraf® for the Treatment of Patients with BRAF Mutation-Positive Metastatic Melanoma
12/12/2011
Plexxikon Advances Novel Targeted Treatment of PLX3397 in Blood Cancer
11/13/2011
Plexxikon Novel Agents Aim To Address Cancer Treatment in New Ways
8/17/2011
Plexxikon Announces FDA Approval of Zelboraf™ (vemurafenib) and Companion Diagnostic for the Treatment of Patients with BRAF Mutation-Positive Metastatic Melanoma
6/5/2011
Plexxikon Reports Positive Data from Phase 3 and Phase 2 Trials of Vemurafenib (PLX4032)
6/2/2011
Plexxikon Announces Combination Trials for Vemurafenib in Melanoma
5/18/2011
Plexxikon Announces Data Presentations of Oncology Pipeline, Including Phase 3 Vemurafenib Data, at ASCO 2011 Annual Meeting
5/10/2011
New Drug Applications Submitted for Vemurafenib Market Approval in Melanoma
4/4/2011
Daiichi Sankyo Completes Plexxikon Acquisition
3/8/2011
Plexxikon Initiates Phase 2 Clinical Trial in Hodgkin Lymphoma with PLX3397
2/28/2011
Daiichi Sankyo To Acquire Plexxikon
1/27/2011
Plexxikon Initiates Phase 1 Clinical Trial for Oral Rheumatoid Arthritis Agent PLX5622
1/18/2011
Plexxikon Reports Overall Survival Benefit for Melanoma Patients in PLX4032 Phase 3 Trial
1/6/2011
Plexxikon Signs Agreement with Genentech to Co-Promote PLX4032 in the US
Archived Press Releases
